Daiichi Sankyo Pharmaceutical Jobs

PharmaDiversityJobBoard-Diversity Job Board connecting diversity & minority job seekers with Pharmaceutical jobs.

Home | Login | Job Seeker Register | Employer Register You're not logged in!

Translate:

Daiichi Sankyo Jobs

Click links to read Current News for this Featured Employer Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile | Daiichi Sankyo Settled Patent Litigation for Evoxac® | DAIICHI SANKYO EUROPE GmbH Selects DATATRAK eClinical? for Pan-European Systolic Hypertension Study | FDA Approves Tribenzor?, A New Three-In-One Combination Product for the Treatment of High Blood Pressure | New Data Shows Investigational Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes | Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy | Students 2 Science and Daiichi Sankyo, Inc. Help Students Learn Through Hands-On Experience | Three Out of Four Patients Uncontrolled on Monotherapy Achieved Blood Pressure Goal with AZOR(R) According to New Study Results | New Data Demonstrate Welchol(R) (colesevelam HCl) Significantly Improved Lipid and Glycemic Measures in Patients With High LDL Cholesterol and Prediabetes | Daiichi Sankyo Submits First New Drug Application for Oral Factor Xa Inhibitor, Edoxaban | Millions of Americans Could Have a Disease That is Overlooked or Misdiagnosed | Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair | FDA Approves Benicar(R) for the Treatment of High Blood Pressure in Children and Adolescents aged 6-16 | Daiichi Sankyo, Inc. Names Dr. Jay Feingold Vice President, Medical Affairs | Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism | New Analysis Showed Effient(R) Cost-Effective Compared with Clopidogrel for Patients with Acute Coronary Syndromes Undergoing PCI | Boston Scientific Announces Enrollment of First Patient in Post-Approval Study for TAXUS Liberte Stent | Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target | Elsevier Vice Chairman Chi to Lead Science & Technology Division | Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease | Welchol(R) (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in Pediatric Patients with Heterozygous Familial Hypercholesterolemia Welchol for Oral Suspension Also Approved by FDA | Survivors of Heart Events: What Does it Take to Get Back to Living? New program helps educate survivors of a heart event about the importance of maintaining good physical and emotional health | Ranbaxy Launches Authorized Generic Version of Rocaltrol(R) Agreement with Validus Pharmaceuticals to Market and Distribute Multiple Formulations in the U.S. Healthcare System | Ranbaxy Receives Final Approval To Market Sumatriptan Succinate Tablets Ranbaxy expands product portfolio by offering all strengths of Sumatriptan tablets | Effient(TM) is Now Available in Pharmacies Effient(TM) Reduces Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndromes Managed with Common Artery-Opening Procedure | Analysis of Edoxaban Phase II Data Provides Insight Into Reduced Bleeding Events Seen in Once-Daily Dosing - Pharmacokinetic Analysis of Atrial Fibrillation Study May Explain Bleeding Rate Difference between Once-Daily and Twice-Daily Dosing Regimens with Same Total Exposure of Factor Xa Inhibitor - | Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM) Effient(TM) Reduces Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndromes Managed with Common Artery-Opening Procedure | Nation's First Eco-Friendly Mobile Health Van Launched by New Jersey Non-Profit Health Center | Studiocom Continues Growth with Healthcare Industry Wins | Multiple Types of Heart Attacks Reduced by Prasugrel in TRITON-TIMI 38 Trial | Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes | AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure | New Data Shows AZOR(R) (amlodipine and olmesartan medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure | New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure | Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results | New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel | The American Society of Hypertension Launches Education Program for Hypertension Accreditation | Smith & Nephew Introduces Metal Liner Option for the Modular R3(TM) Acetabular Cup System | Prasugrel Receives Unanimous Approval Recommendation from FDA Advisory Committee | Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico | Daiichi Sankyo, Inc. Awarded Prestigious NCQA Certification for National Under Pressure(TM) Hypertension Management Program | New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation | Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation | New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation | Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation | Daiichi Sankyo, Inc. Announces Three Studies of Oral Factor Xa Inhibitor DU-176b Accepted for the 50th Annual Meeting of the American Society of Hematology | Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death | Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application | Daiichi Sankyo, Inc. Files Supplemental New Drug Application for AZOR(R) as Initial Therapy for High Blood Pressure |

Save	Date	Job Title	City Country	State	Company Name	Pay
Items 1-25/113 displayed. [1-25][26-50][51-75][76-100][101-113] next
	Sep 03	Director, Global Project Management	Edison	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Analyst, Regional Market Planning	Parsippany	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Terre Haute, IN	Terre Haute	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Las Cruces, NM	Las Cruces	New Mexico	Daiichi Sankyo	Not specified
	Sep 03	Project Data Manager	Edison	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 2 - Billings, MT	Billings	Montana	Daiichi Sankyo	Not specified
	Sep 03	District Manager, Primary Care 3 - Oklahoma City, OK	Oklahoma City	Oklahoma	Daiichi Sankyo	Not specified
	Sep 03	Hospital Sales Representative, Westchester, NY	Westchester	New York	Daiichi Sankyo	Not specified
	Sep 03	Director, Modeling and Simulation	Edison	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Hospital Sales Representative, Mobile, AL	Mobile	Alabama	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 2 - New Rochelle, NY	New Rochelle	New York	Daiichi Sankyo	Not specified
	Sep 03	Hospital Sales Representative, Pittsburgh South, PA	Pittsburgh	Pennsylvania	Daiichi Sankyo	Not specified
	Sep 03	Director, Biostatistics and Data Management	Parsippany	New Jersey	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Kingsport, TN	Kingsport	Tennessee	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Jackson South, MS	Jackson	Mississippi	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 2 - Asheboro, NC	Asheboro	North Carolina	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Lansdale, PA	Lansdale	Pennsylvania	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Lafayette, IN	Lafayette	Indiana	Daiichi Sankyo	Not specified
	Sep 03	Hospital Sales Representative, Baltimore NE, MD	Baltimore	Maryland	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Wilkes Barre, PA	Wilkes Barre	Pennsylvania	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - New Haven, CT	New Haven	Connecticut	Daiichi Sankyo	Not specified
	Sep 03	District Manager, Primary Care 3 - Columbus, OH	Columbus	Ohio	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Charleston, SC	Charleston	South Carolina	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 3 - Baltimore West, MD	Baltimore	Maryland	Daiichi Sankyo	Not specified
	Sep 03	Sales Representative, Primary Care 1 - Houston Medical Center, TX	Houston	Texas	Daiichi Sankyo	Not specified